Call Us: +31 (0) 73 - 627 4520 - Mail info@immunovo.com

Who we are

Immunovo BV is a Dutch private biotechnology company, based in ‘s-Hertogenbosch, engaged in the discovery and clinical development of immunotherapeutics in the field of oncology. The key priority for Immunovo is on its proprietary Immune Activation System (IAS*) based on combining synthetic peptide antigens with a novel immune stimulant (adjuvant).   IAS* has the potential to be a truly disruptive technology in the immunotherapeutic field as crucially there are fewer economic factors in place which restrict access to wider numbers of patients in comparison to currently prescribed drugs. Read more

What we do

Immunotherapy is a rapidly emerging field providing promising new therapies for cancer and other presently incurable diseases. A major attraction of this approach is that it sets out to deliver precisely aimed therapies with significantly reduced risk of side effects and discomfort for the patient. Immunotherapy harnesses the immune system either via elimination or arresting the growth of undesired cells (cancer) or controlling diseases caused by normal biochemical processes that have gone out of control (Alzheimer, hypertension, Crohn’s disease, rheumatoid arthritis, osteoporosis, etc).
Read more

Latest News items

Back to Top